TAK-875(Fasiglifam),GPR40Agonist

Biological Activity:

TAK-875 (Fasiglifam) is the potent, selective and orally bioavailable partial GPR40 agonist with an EC₅₀ ~14 nM.  It has binding affinity to the human GPR40 receptor with Ki of 38 nM and the rat GPR40 receptor with Ki of 140 nM. TAK-875 has no agonist potency to other members of the FFA receptor family with EC₅₀ >10 μM. The 2.3 Å resolution co-complex structure of hGPR40-TAK-875 reveals a unique binding mode of TAK-875 and suggests that entry to the non-canonical binding pocket most probably occurs via the lipid bilayer. Consistent with the activation of the Gqα-mediated signaling pathway, TAK-875 augments glucose-dependent insulin secretion in pancreatic β cells. Prolonged stimulation of GPR40/FFA1 by TAK-875 does not cause pancreatic β Cell dysfunction or induction of apoptosis. Termination phase III development of TAK-875 (Fasiglifam) for the potential treatment of type-2 diabetes mellitus was announced in 2013 due to concerns about liver safety.

How to Use:

• In vitro:  TAK-875 was used at 1 µM final concentration in various in vitro assays.
• In vivo: TAK-875 was dosed to female Wistar fatty rats subjected to oral glucose tolerance test via oral gavage at 3 mg/kg one hour before an oral glucose challenge. Formulation is 0.5% CMC/0.25% Tween 80 in water. In type 2 diabetic N-STZ-1.5 rats, administration of TAK-875 (1-10 mg/kg PO) shows a clear improvement in glucose tolerance and augments insulin secretion. TAK-875 (10 mg/kg, PO) significantly augments plasma insulin levels and reduces fasting hyperglycemia in male Zucker diabetic fatty rats. 

Reference: 

1. 1.      Negoro N, et al. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. (2010) ACS Med Chem Lett. 1(6):290-4.
2. 2.      Tsujihata Y, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. (2011) J Pharmacol Exp Ther. 339(1):228-37.
3. 3.      Srivastava A, et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. (2014) Nature. 513(7516):124-7. 

产品留言

标题

联系人

联系电话

内容

验证码

点击换一张

注：1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!